On June 12, 2025, Needham analyst Mike Matson released a new report on Conmed (CNMD, Financial), announcing a downgrade in the stock's rating from "Buy" to "Hold". This change reflects a more cautious stance on the stock.
Despite the downgrade, Needham has maintained its price target for Conmed (CNMD, Financial) at $61.00, unchanged from the prior target. This indicates that while the long-term prospects of the company are still seen as stable, immediate upside potential might be limited.
Investors should note that the price target is denominated in USD and reflects Needham's current expectations for Conmed's (CNMD, Financial) stock performance in the coming periods.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for Conmed Corp (CNMD, Financial) is $67.20 with a high estimate of $80.00 and a low estimate of $57.00. The average target implies an upside of 18.00% from the current price of $56.95. More detailed estimate data can be found on the Conmed Corp (CNMD) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Conmed Corp's (CNMD, Financial) average brokerage recommendation is currently 2.7, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Conmed Corp (CNMD, Financial) in one year is $114.27, suggesting a upside of 100.65% from the current price of $56.95. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Conmed Corp (CNMD) Summary page.
